Compare Stocks

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZRX AzurRx BioPharma	$2.73 -9.6%	$4.04	$3.36 ▼ $26.30	$25.46M	1.51	628,703 shs	45,267 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs
OHRP OHR Pharmaceutical	$0.44 +4.7%	$7.37	$1.60 ▼ $6.28	$1.25M	0.84	180,228 shs	25,641 shs
SXTC China SXT Pharmaceuticals	$1.07 +3.9%	$1.70	$0.94 ▼ $9.38	$492K	1	1.03 million shs	119,625 shs
UMRX Cogent Biosciences	$6.01 -8.1%	$10.50	$0.29 ▼ $3.72	$255.24M	3.93	1.22 million shs	1.21 million shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZRX AzurRx BioPharma	-3.21%	+6.34%	-23.93%	-38.99%	+5.96%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
OHRP OHR Pharmaceutical	0.00%	+0.26%	-12.07%	-32.12%	+220.64%
SXTC China SXT Pharmaceuticals	-3.74%	+4.04%	-38.69%	-44.02%	-79.10%
UMRX Cogent Biosciences	0.00%	-1.06%	+12.08%	+47.63%	-39.33%

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	$3.86 per share	N/A
SXTC China SXT Pharmaceuticals	$1.97M	0.25	N/A	N/A	$32.12 per share	0.03
UMRX Cogent Biosciences	$22.50M	11.34	N/A	N/A	$1.04 per share	5.78

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A
OHRP OHR Pharmaceutical	-$13.23M	N/A	0.00	∞	N/A	N/A	-75.46%	-71.18%	N/A
SXTC China SXT Pharmaceuticals	-$5.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/29/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZRX AzurRx BioPharma	N/A	1.33	1.33
NTEC Intec Pharma	N/A	2.34	2.34
OHRP OHR Pharmaceutical	N/A	3.73	3.73
SXTC China SXT Pharmaceuticals	0.02	1.47	1.41
UMRX Cogent Biosciences	0.18	2.90	2.90

Ownership

Institutional Ownership

Company	Institutional Ownership
AZRX AzurRx BioPharma	6.27%
NTEC Intec Pharma	22.37%
OHRP OHR Pharmaceutical	10.70%
SXTC China SXT Pharmaceuticals	5.02%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
AZRX AzurRx BioPharma	7.30%
NTEC Intec Pharma	3.30%
OHRP OHR Pharmaceutical	12.50%
SXTC China SXT Pharmaceuticals	3.95%
UMRX Cogent Biosciences	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
NTEC Intec Pharma	40	898,000	N/A	Optionable
OHRP OHR Pharmaceutical	3	2.83 million	N/A	Not Optionable
SXTC China SXT Pharmaceuticals	78	460,000	439,000	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

NTEC, SXTC, AZRX, UMRX, and OHRP Headlines

Source	Headline
	Cogent Biosciences Inc money.usnews.com - April 24 at 4:34 AM
	Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) markets.businessinsider.com - February 26 at 5:33 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) markets.businessinsider.com - February 26 at 8:53 AM
	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 26 at 8:53 AM
	Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential markets.businessinsider.com - February 15 at 8:43 AM
	Cogent Biosciences Stock Soars After $225M Private Placement marketwatch.com - February 14 at 10:02 AM
	Cogent Biosciences announces oversubscribed $225M private placement msn.com - February 14 at 10:02 AM
	Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects markets.businessinsider.com - February 9 at 2:23 AM
	Citi starts Cogent Biosciences at buy, cites GI tumor drug potential msn.com - February 8 at 4:22 PM
	Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial markets.businessinsider.com - December 15 at 7:55 PM
	Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib markets.businessinsider.com - December 13 at 5:33 PM
	Dow Surges 100 Points; Cogent Biosciences Shares Plunge markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis markets.businessinsider.com - December 11 at 10:08 AM
	Cogent slumps after mid-stage data for rare disorder therapy msn.com - December 11 at 10:08 AM
	Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares markets.businessinsider.com - November 21 at 9:11 AM
	Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences markets.businessinsider.com - November 14 at 8:40 AM
	Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences markets.businessinsider.com - November 4 at 5:21 PM
	Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating markets.businessinsider.com - October 28 at 7:55 AM
	Analyst Expectations for Cogent Biosciences's Future benzinga.com - August 30 at 8:53 AM
	Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor msn.com - August 15 at 5:40 PM
	LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) markets.businessinsider.com - August 8 at 3:59 PM
	Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect? msn.com - July 11 at 1:47 PM
	Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition marketwatch.com - June 13 at 11:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
April 25, 2024 10:36 AM
View Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Pagaya Technologies: An AI Fintech That Insiders Are Buying
April 24, 2024 11:12 AM
View Pagaya Technologies: An AI Fintech That Insiders Are Buying

All Headlines

Company Descriptions

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Intec Pharma

NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

OHR Pharmaceutical

NASDAQ:OHRP

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

China SXT Pharmaceuticals

NASDAQ:SXTC

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial